Natasha Barrow

Natasha Barrow

Reporter - Medtech Insight

London

Natasha holds first-class honors in Biological Sciences from the University of Leeds. She completed an industrial placement with Johnson & Johnson during her degree, working in medical device regulatory affairs. After graduating from university, she worked for regulatory consultancy firm JensonR+ across medicines, medical devices, food supplements, and cosmetics. In 2022, she moved to London to work for the UK consumer healthcare association. She joined Medtech Insight in November 2023 and reports on the latest commercial and policy developments in diagnostics and AI digital technologies, covering therapeutic areas such as cancer and cardiology.

Latest from Natasha Barrow

‘AI Isn’t Flying Off The Shelves In The NHS,’ Says Healthtech Startup CEO

Vendor exhaustion, insufficient clinical-grade evidence, and outdated risk management are some of the reasons the NHS is struggling to adopt AI. Haris Shuaib, CEO of Newton's Tree, shared his insights with the audience at the “Next Frontier of Medical AI” event held at DAC Beachcroft's London office on 23 April.

‘The FDA Will Be Looking For Avenues To Regulate Laboratory Developed Tests’

The FDA's final LDT ruling was struck down in federal court last month. For now, diagnostic companies can commercialize under CLIA regulations or apply for FDA approval. McDermott and Tribun Health have shared insights on the risks, pros and cons of both regulatory routes.

First Liver Cancer Surveillance Test In Five Years Receives FDA Breakthrough Status

Cambridge-based startup Mursla Bio's liquid biopsy test EvoLiver uses extracellular vesicles to detect hepatocellular carcinoma (HCC) in high-risk cirrhotic patients. Medtech Insight sat down with with Mursla Bio CEO Pierre Arsène.

OneCell Diagnostics – Now 1Cell.Ai - Launches Multi-Modal Cancer Diagnostic Panel OncoIncytes

OneCell Diagnostics, the Mumbai-based startup backed with $16m in series A funding, is rebranding to 1Cell.Ai to represent the firm's focus on combining deep science with AI-powered capabilities.

Edwards Mitral Valve Replacement System SAPIEN M3 Receives CE Mark

“We believe [the SAPIEN M3] launch alongside PASCAL and EVOQUE will help support the company’s target of $2bn in transcatheter mitral and tricuspid therapies sales by 2030,” noted analysts from Leerink Partners.

Anglonordic 25: Pictura Bio’s One-Minute Pathogen-Identifying Diagnostic Test

“Infectious disease should be treated in the community, not in hospitals,” Alex Batchelor, Pictura Bio CEO, told Medtech Insight at the Anglonordic Life Science Conference on 3 April in London.